EUVIMEDEUVIMED entdecken
MetaanalyseFallberichtOpen Access · CC BY-NC 4.0

Anti‐ PD ‐(L)1 Antibodies: Insights From QSP ‐Based Meta‐Analysis

Carter L Johnson, Deborah A Flusberg, Sarah A Head, David Flowers iD, Andrew Matteson, Diana H Marcantonio, John M Burke, Joshua F Apgar iD, Georgi I Kapitanov

CPT: Pharmacometrics & Systems Pharmacology · 2026

DOI: 10.1002/psp4.70195 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von Carter L Johnson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Certara Predictive Technologies, Sheffield, UK. Hauptthemen laut MEDLINE: B7-H1 Antigen, Antibodies, Monoclonal, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Checkpoint inhibitors that target PD‐1 or PD‐L1 have had a profound effect in a variety of cancers, both as a single therapy and in combinations. Meta‐analyses suggest that monoclonal antibodies (mAbs) targeting PD‐1 may yield better survival outcomes compared to anti‐PD‐L1 mAbs, however these conclusions are limited by a lack of direct clinical comparisons between the two classes. There is a shared hypothesis for the mechanism of action of these drugs: inhibition of the PD‐1:PD‐L1 signaling pathway through binding to either target. Using a Quantitative Systems Pharmacology (QSP) model‐based analysis, we test whether differential inhibition of PD‐1:PD‐L1 complex formation (a surrogate for inhibition of the signaling pathway) is sufficient to explain the efficacy difference between anti‐PD‐1 and anti‐PD‐L1 mAbs observed in clinical meta‐analyses. The model predicts that high levels of PD‐1:PD‐L1 complex inhibition are achieved by all the considered mAbs at their clinical dosing regimens, but it does not indicate that anti‐PD‐1 mAbs yield higher inhibition over anti‐PD‐L1s, in contrast to the meta‐analyses. Significant model parameter variability and a bootstrap sampling analysis mirroring the comparison from Duan et al. (2020) do not change this conclusion. This suggests that anti‐PD‐1 and anti‐PD‐L1 mAbs are not differentiable based on PD‐1:PD‐L1 complex inhibition alone, and that the hypothesized shared mechanism of action of the two classes of drugs is incomplete.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenAntibodies, MonoclonalProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsNeoplasmsAntineoplastic Agents, ImmunologicalHumansSignal Transduction

Stichwörter der Autor:innen

PD‐1PD‐L1Vpopcheckpoint inhibitionmeta‐analysisquantitative systems pharmacology

Substanzen

B7-H1 AntigenAntibodies, MonoclonalProgrammed Cell Death 1 ReceptorCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Certara Predictive Technologies, Sheffield, UK.
  • Reverb Therapeutics, Cambridge, Massachusetts, USA.

ORCID-Profile: David Flowers, Joshua F Apgar

Zitieren

APA

Johnson, C. L., Flusberg, D. A., Head, S. A., Flowers, D., Matteson, A., Marcantonio, D. H., Burke, J. M., Apgar, J. F., & Kapitanov, G. I. (2026). Anti‐ PD ‐(L)1 Antibodies: Insights From QSP ‐Based Meta‐Analysis. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70195

Vancouver

Johnson CL, Flusberg DA, Head SA, Flowers D, Matteson A, Marcantonio DH, et al. Anti‐ PD ‐(L)1 Antibodies: Insights From QSP ‐Based Meta‐Analysis. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70195

BibTeX
@article{Johnson2026,
  author = {Johnson, Carter L and Flusberg, Deborah A and Head, Sarah A and Flowers, David and Matteson, Andrew and Marcantonio, Diana H and Burke, John M and Apgar, Joshua F and Kapitanov, Georgi I},
  title = {Anti‐ PD ‐(L)1 Antibodies: Insights From QSP ‐Based Meta‐Analysis},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  doi = {10.1002/psp4.70195}
}
Kostenlos starten →